You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiflunisal
Accession NumberDB00861  (APRD00922, DB06895)
TypeSmall Molecule
GroupsApproved
DescriptionDiflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
Structure
Thumb
Synonyms
2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid
2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid
5-(2,4-Difluorophenyl)salicylic acid
Diflunisal
Diflunisal
Diflunisal
Diflunisalum
Dolobid
External Identifiers
  • MK 647
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DiflunisalTablet500 mgOralAa Pharma Inc1993-12-31Not applicableCanada
DiflunisalTablet250 mgOralAa Pharma Inc1993-12-31Not applicableCanada
Diflunisal-250 - Tab 250mgTablet250 mgOralPro Doc Limitee1995-12-312000-07-31Canada
Diflunisal-500 - Tab 500mgTablet500 mgOralPro Doc Limitee1995-12-312000-07-31Canada
Dolobid Tab 250mgTablet250 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-311998-08-14Canada
Dolobid Tab 500mgTablet500 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-312000-08-03Canada
Novo-diflunisalTablet250 mgOralTeva Canada Limited1993-12-31Not applicableCanada
Novo-diflunisalTablet500 mgOralTeva Canada Limited1993-12-31Not applicableCanada
Nu-diflunisal Tab 250mgTablet250 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Nu-diflunisal Tab 500mgTablet500 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DiflunisalTablet, film coated500 mg/1OralA S Medication Solutions Llc1992-11-01Not applicableUs
DiflunisalTablet, film coated500 mg/1OralTeva Pharmaceuticals Usa, Inc.1992-11-01Not applicableUs
DiflunisalTablet, film coated500 mg/1OralPhysicians Total Care, Inc.2009-07-21Not applicableUs
DiflunisalTablet, film coated500 mg/1OralRising Pharmaceuticals Inc.2012-05-01Not applicableUs
DiflunisalTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2010-08-20Not applicableUs
DiflunisalTablet, film coated500 mg/1OralA S Medication Solutions1992-11-01Not applicableUs
DiflunisalTablet, film coated500 mg/1OralCarilion Materials Management1992-11-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AntonEverest
DolobidMerck
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7C546U4DEN
CAS number22494-42-4
WeightAverage: 250.1976
Monoisotopic: 250.044150532
Chemical FormulaC13H8F2O3
InChI KeyHUPFGZXOMWLGNK-UHFFFAOYSA-N
InChI
InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
IUPAC Name
5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
SMILES
OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
Pharmacology
IndicationFor symptomatic treatment of mild to moderate pain accompanied by inflammation (e.g. musculoskeletal trauma, post-dental extraction, post-episiotomy), osteoarthritis, and rheumatoid arthritis.
Structured Indications
PharmacodynamicsDiflunisal is a nonsteroidal drug with analgesic, anti-inflammatory and antipyretic properties. It is a peripherally-acting non-narcotic analgesic drug. Habituation, tolerance and addiction have not been reported. Diflunisal is a difluorophenyl derivative of salicylic acid. Chemically, diflunisal differs from aspirin (acetylsalicylic acid) in two respects. The first of these two is the presence of a difluorophenyl substituent at carbon 1. The second difference is the removal of the 0-acetyl group from the carbon 4 position. Diflunisal is not metabolized to salicylic acid, and the fluorine atoms are not displaced from the difluorophenyl ring structure.
Mechanism of actionThe precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due to a decrease of prostaglandins in peripheral tissues.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionRapidly and completely absorbed following oral administration, with a bioavailability of 80-90%. Peak plasma concentrations are achieved 2 - 3 hours following oral administration.
Volume of distributionNot Available
Protein bindingAt least 98 to 99% of diflunisal in plasma is bound to proteins.
Metabolism

Hepatic, primarily via glucuronide conjugation (90% of administered dose).

Route of eliminationThe drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces.
Half life8 to 12 hours
ClearanceNot Available
ToxicityOral LD50 in rat, mouse, and rabbit is 392 mg/kg, 439 mg/kg, and 603 mg/kg, respectively. Symptoms of overdose include drowsiness, nausea, vomiting, diarrhea, hyperventilation, tachycardia, sweating, tinnitus, disorientation, stupor, and coma. The lowest dose without the presence of other medicines which caused death was 15 grams.

Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of diflunisal. Short-term use does not appear to be associated with increased cardiovascular risk (except when used immediately following coronary artery bypass graft (CABG) surgery). Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Severe hepatic reactions, including cholestasis and/or jaundice, have been reported. May cause rash or hypersensitivity syndrome.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Diflunisal Action PathwayDrug actionSMP00289
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Diflunisal is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Diflunisal is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Diflunisal is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Diflunisal.Approved
AcarboseDiflunisal may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololDiflunisal may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aceclofenac.Approved
AcenocoumarolDiflunisal may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Diflunisal.Approved, Vet Approved
AclarubicinDiflunisal may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Diflunisal.Approved
AlbiglutideDiflunisal may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.Approved
AliskirenDiflunisal may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlogliptinDiflunisal may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololDiflunisal may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Diflunisal.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alteplase.Approved
ALX-0081The risk or severity of adverse effects can be increased when Diflunisal is combined with ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Amcinonide.Approved
AmikacinDiflunisal may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideDiflunisal may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Diflunisal.Approved
Ammonium chlorideThe serum concentration of Diflunisal can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AmrubicinDiflunisal may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Diflunisal.Approved
AncrodDiflunisal may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anisodamine.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anistreplase.Approved
annamycinDiflunisal may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Antipyrine.Approved
Antithrombin III humanDiflunisal may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Diflunisal may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanDiflunisal may increase the anticoagulant activities of Apixaban.Approved
ApramycinDiflunisal may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Diflunisal is combined with Apremilast.Approved, Investigational
ArbekacinDiflunisal may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinDiflunisal may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Diflunisal.Approved, Investigational
ArotinololDiflunisal may decrease the antihypertensive activities of Arotinolol.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Astaxanthin.Investigational
AtenololDiflunisal may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Diflunisal.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Diflunisal.Approved
BalsalazideDiflunisal may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Batroxobin.Experimental
BecaplerminDiflunisal may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololDiflunisal may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bemiparin.Approved
BenazeprilDiflunisal may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diflunisal.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Benoxaprofen.Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Diflunisal.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Betamethasone.Approved, Vet Approved
BetaxololDiflunisal may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Betulinic Acid.Investigational
BevantololDiflunisal may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Diflunisal.Approved, Investigational
BisoprololDiflunisal may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinDiflunisal may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololDiflunisal may decrease the antihypertensive activities of Bopindolol.Approved
BrinzolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Brinzolamide.Approved
BromfenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bromfenac.Approved
BromocriptineDiflunisal may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bucillamine.Investigational
BucindololDiflunisal may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Budesonide.Approved
BufuralolDiflunisal may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideDiflunisal may decrease the diuretic activities of Bumetanide.Approved
BupranololDiflunisal may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Diflunisal.Investigational
CanagliflozinDiflunisal may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Diflunisal.Approved
CandoxatrilDiflunisal may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Diflunisal.Approved
CaptoprilDiflunisal may decrease the antihypertensive activities of Captopril.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Diflunisal.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Diflunisal.Approved, Vet Approved, Withdrawn
CarteololDiflunisal may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolDiflunisal may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Celecoxib.Approved, Investigational
CeliprololDiflunisal may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinDiflunisal may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Diflunisal.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diflunisal.Approved, Vet Approved
ChlorpropamideDiflunisal may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diflunisal.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ciclesonide.Approved, Investigational
CilazaprilDiflunisal may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Diflunisal.Approved
CinoxacinDiflunisal may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinDiflunisal may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidDiflunisal may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clonixin.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Diflunisal.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Diflunisal.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Diflunisal is combined with Curcumin.Investigational
CyclosporineDiflunisal may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Diflunisal is combined with D-Limonene.Investigational
Dabigatran etexilateDiflunisal may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinDiflunisal may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDiflunisal may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinDiflunisal may increase the hypoglycemic activities of Dapagliflozin.Approved
DaunorubicinDiflunisal may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Diflunisal is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Diflunisal.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Diflunisal is combined with dehydroepiandrosterone sulfate.Investigational
dersalazineDiflunisal may increase the anticoagulant activities of dersalazine.Investigational
DesirudinDiflunisal may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexketoprofen.Approved
DextranDiflunisal may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Diflunisal may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Diflunisal may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Diflunisal may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Diflunisal.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Diclofenamide.Approved
DicoumarolDiflunisal may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Diflunisal.Approved
DihydrostreptomycinDiflunisal may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Diflunisal.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Diflunisal.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Diflunisal.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Diflunisal.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Diflunisal.Approved
DisopyramideDiflunisal may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dorzolamide.Approved
DoxorubicinDiflunisal may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneDiflunisal may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Diflunisal is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Droxicam.Approved
DulaglutideDiflunisal may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Diflunisal is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ebselen.Investigational
Edetic AcidDiflunisal may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDiflunisal may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinDiflunisal may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilDiflunisal may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatDiflunisal may decrease the antihypertensive activities of Enalaprilat.Approved
EnoxacinDiflunisal may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinDiflunisal may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Diflunisal.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Epirizole.Approved
EpirubicinDiflunisal may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneDiflunisal may decrease the antihypertensive activities of Eplerenone.Approved
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Diflunisal.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Diflunisal.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diflunisal.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Diflunisal.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Diflunisal is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Equilin.Approved
EsmololDiflunisal may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone sulfate.Approved
Etacrynic acidDiflunisal may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Diflunisal.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateDiflunisal may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Diflunisal is combined with Evening primrose oil.Approved
ExenatideDiflunisal may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Diflunisal is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Diflunisal.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Diflunisal.Vet Approved
FibrinolysinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fibrinolysin.Approved
FleroxacinDiflunisal may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Diflunisal.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fludrocortisone.Approved
FluindioneDiflunisal may increase the anticoagulant activities of Fluindione.Investigational
FlumequineDiflunisal may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Diflunisal.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Diflunisal.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Diflunisal.Approved, Nutraceutical, Vet Approved
FondaparinuxDiflunisal may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDiflunisal may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Diflunisal.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilDiflunisal may decrease the antihypertensive activities of Fosinopril.Approved
FramycetinDiflunisal may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideDiflunisal may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateDiflunisal may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinDiflunisal may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinDiflunisal may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Diflunisal.Approved, Withdrawn
GemifloxacinDiflunisal may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinDiflunisal may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinDiflunisal may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ADiflunisal may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Diflunisal.Approved, Nutraceutical
GliclazideDiflunisal may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDiflunisal may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDiflunisal may increase the hypoglycemic activities of Glipizide.Approved
GlyburideDiflunisal may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinDiflunisal may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Diflunisal is combined with HE3286.Investigational
HeparinDiflunisal may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Higenamine.Investigational
HirulogDiflunisal may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Diflunisal is combined with HMPL-004.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diflunisal.Approved, Investigational
HydralazineDiflunisal may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diflunisal.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Diflunisal.Approved
Hygromycin BDiflunisal may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Diflunisal.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Diflunisal is combined with Icatibant.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Diflunisal.Approved, Nutraceutical
IdarubicinDiflunisal may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxDiflunisal may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Diflunisal.Approved, Withdrawn
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Diflunisal.Approved, Investigational
ImidaprilDiflunisal may decrease the antihypertensive activities of Imidapril.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diflunisal.Approved
IndenololDiflunisal may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diflunisal.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Indoprofen.Withdrawn
INNO-206Diflunisal may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Insulin AspartDiflunisal may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDiflunisal may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDiflunisal may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDiflunisal may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDiflunisal may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDiflunisal may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diflunisal.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Diflunisal is combined with Istaroxime.Investigational
KanamycinDiflunisal may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
Kct 0809The risk or severity of adverse effects can be increased when Diflunisal is combined with Kct 0809.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Kebuzone.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Diflunisal.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Diflunisal.Approved
LabetalolDiflunisal may decrease the antihypertensive activities of Labetalol.Approved
LanreotideDiflunisal may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Diflunisal.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Leflunomide.Approved, Investigational
LepirudinDiflunisal may increase the anticoagulant activities of Lepirudin.Approved
LevobunololDiflunisal may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinDiflunisal may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Diflunisal.Approved
LiraglutideDiflunisal may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilDiflunisal may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Diflunisal.Approved
LomefloxacinDiflunisal may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Diflunisal.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Diflunisal.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Diflunisal.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Diflunisal.Approved
ME-609The risk or severity of adverse effects can be increased when Diflunisal is combined with ME-609.Investigational
MecaserminDiflunisal may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Diflunisal.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Diflunisal.Approved, Vet Approved
MesalazineDiflunisal may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Metamizole.Withdrawn
MetforminDiflunisal may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Diflunisal.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Methylprednisolone.Approved, Vet Approved
MetipranololDiflunisal may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal.Approved
MetoprololDiflunisal may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideDiflunisal may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneDiflunisal may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolDiflunisal may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Diflunisal.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Diflunisal.Approved
MizoribineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mizoribine.Investigational
MoexiprilDiflunisal may decrease the antihypertensive activities of Moexipril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Diflunisal.Approved
MoxifloxacinDiflunisal may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Diflunisal.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nabumetone.Approved
NadololDiflunisal may decrease the antihypertensive activities of Nadolol.Approved
NadroparinDiflunisal may increase the anticoagulant activities of Nadroparin.Approved
NafamostatDiflunisal may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Diflunisal.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Diflunisal.Investigational
Nalidixic AcidDiflunisal may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Diflunisal.Approved, Vet Approved
NateglinideDiflunisal may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Diflunisal is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Diflunisal.Investigational
NeamineDiflunisal may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinDiflunisal may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinDiflunisal may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nepafenac.Approved
NetilmicinDiflunisal may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Diflunisal.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Diflunisal.Investigational
NorfloxacinDiflunisal may increase the neuroexcitatory activities of Norfloxacin.Approved
OctreotideDiflunisal may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OfloxacinDiflunisal may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diflunisal.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflunisal.Approved
OlsalazineDiflunisal may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatDiflunisal may decrease the antihypertensive activities of Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Orgotein.Vet Approved
OtamixabanDiflunisal may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxaprozin.Approved
OxprenololDiflunisal may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Parnaparin.Approved
ParomomycinDiflunisal may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PasireotideDiflunisal may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinDiflunisal may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinDiflunisal may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololDiflunisal may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineDiflunisal may increase the hypoglycemic activities of Pentamidine.Approved
Pentosan PolysulfateDiflunisal may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Diflunisal.Approved, Investigational
PerindoprilDiflunisal may decrease the antihypertensive activities of Perindopril.Approved
PhenindioneDiflunisal may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonDiflunisal may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Diflunisal.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diflunisal.Approved, Investigational
PindololDiflunisal may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneDiflunisal may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirarubicinDiflunisal may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideDiflunisal may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflunisal.Approved, Investigational
PlasminThe risk or severity of adverse effects can be increased when Diflunisal is combined with Plasmin.Investigational
PlicamycinDiflunisal may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Diflunisal.Approved
PractololDiflunisal may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Diflunisal.Approved
PramlintideDiflunisal may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prasterone.Approved, Nutraceutical
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Diflunisal.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pregnenolone.Experimental
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Diflunisal.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Propacetamol.Approved
PropranololDiflunisal may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Diflunisal.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Diflunisal.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Diflunisal.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Diflunisal.Vet Approved
Protein CDiflunisal may increase the anticoagulant activities of Protein C.Approved
Protein S humanDiflunisal may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDiflunisal may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinDiflunisal may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Diflunisal is combined with PTC299.Investigational
PuromycinDiflunisal may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilDiflunisal may decrease the antihypertensive activities of Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Diflunisal.Approved
QuinineDiflunisal may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Diflunisal.Investigational
RamiprilDiflunisal may decrease the antihypertensive activities of Ramipril.Approved
RepaglinideDiflunisal may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineDiflunisal may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Diflunisal.Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Reteplase.Approved
ReviparinDiflunisal may increase the anticoagulant activities of Reviparin.Approved
RibostamycinDiflunisal may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Diflunisal.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Risedronate.Approved, Investigational
RivaroxabanDiflunisal may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Rosiglitazone.Approved, Investigational
RosoxacinDiflunisal may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Diflunisal.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diflunisal.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Diflunisal.Investigational
SaxagliptinDiflunisal may increase the hypoglycemic activities of Saxagliptin.Approved
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Diflunisal.Investigational
SelexipagThe risk or severity of adverse effects can be increased when Diflunisal is combined with Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Diflunisal is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Diflunisal.Approved, Vet Approved
SisomicinDiflunisal may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitagliptinDiflunisal may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SotalolDiflunisal may decrease the antihypertensive activities of Sotalol.Approved
SP1049CDiflunisal may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinDiflunisal may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinDiflunisal may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilDiflunisal may decrease the antihypertensive activities of Spirapril.Approved
SpironolactoneDiflunisal may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Diflunisal.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Streptokinase.Approved
StreptomycinDiflunisal may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinDiflunisal may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineDiflunisal may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleDiflunisal may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineDiflunisal may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleDiflunisal may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Diflunisal.Approved
SulodexideDiflunisal may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Diflunisal.Investigational
SunitinibDiflunisal may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Suprofen.Approved, Withdrawn
TacrolimusDiflunisal may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Diflunisal.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Diflunisal.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Diflunisal.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diflunisal.Approved, Investigational
TemafloxacinDiflunisal may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilDiflunisal may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tenecteplase.Approved
TenofovirThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Diflunisal.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Teriflunomide.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Diflunisal.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Diflunisal.Approved
TiludronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiludronate.Approved, Vet Approved
TimololDiflunisal may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tinzaparin.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Diflunisal.Approved
TixocortolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tixocortol.Approved
TobramycinDiflunisal may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideDiflunisal may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideDiflunisal may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diflunisal.Approved
TorasemideDiflunisal may decrease the diuretic activities of Torasemide.Approved
TrandolaprilDiflunisal may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Diflunisal.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Diflunisal.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diflunisal.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diflunisal.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triamcinolone.Approved, Vet Approved
TriamtereneDiflunisal may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diflunisal.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Diflunisal.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Trisalicylate-choline.Approved
TrovafloxacinDiflunisal may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Diflunisal.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Diflunisal.Approved, Investigational
ValrubicinDiflunisal may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Diflunisal.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Diflunisal.Approved
VerapamilVerapamil may increase the anticoagulant activities of Diflunisal.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Diflunisal.Approved
WarfarinDiflunisal may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDiflunisal may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Diflunisal may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Diflunisal.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zomepirac.Withdrawn
ZorubicinDiflunisal may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Food slightly delays rate of absorption with no effect on extent of absorption.
  • Take with food to reduce gastric irritation.
References
Synthesis Reference

Ruyle, W.V., Jarett, L.H. and Matzuk, A.R. ; U S . Patent 3,714,226; January 30, 1973; assigned to Merck & Co., Inc.

General ReferencesNot Available
External Links
ATC CodesN02BA11
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (94.1 KB)
MSDSDownload (73.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9945
Blood Brain Barrier+0.8047
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.6927
P-glycoprotein inhibitor INon-inhibitor0.9407
P-glycoprotein inhibitor IINon-inhibitor0.9735
Renal organic cation transporterNon-inhibitor0.911
CYP450 2C9 substrateNon-substrate0.7982
CYP450 2D6 substrateNon-substrate0.9201
CYP450 3A4 substrateNon-substrate0.7145
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.6684
CYP450 2D6 inhibitorNon-inhibitor0.9357
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5156
Ames testNon AMES toxic0.9666
CarcinogenicityNon-carcinogens0.7828
BiodegradationNot ready biodegradable0.988
Rat acute toxicity2.7735 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.983
hERG inhibition (predictor II)Non-inhibitor0.9178
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
TabletOral250 mg
TabletOral500 mg
Tablet, film coatedOral500 mg/1
Prices
Unit descriptionCostUnit
Dolobid 60 500 mg tablet Bottle92.83USD bottle
Diflunisal 250 mg tablet1.74USD tablet
Diflunisal powder1.56USD g
Diflunisal 500 mg tablet1.46USD tablet
Apo-Diflunisal 500 mg Tablet0.75USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point210-211Ruyle, W.V., Jarett, L.H. and Matzuk, A.R. ; U S . Patent 3,714,226; January 30, 1973; assigned to Merck & Co., Inc.
water solubilityPractically insoluble (14.5 mg/L) at neutral or acidic pH.Not Available
logP4.44SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0711 mg/mLALOGPS
logP3.11ALOGPS
logP3.91ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)2.69ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity60.86 m3·mol-1ChemAxon
Polarizability22.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0fai-1690000000-d231ff5a9ac7d9769d2dView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBiphenyls and derivatives
Direct ParentBiphenyls and derivatives
Alternative Parents
Substituents
  • Biphenyl
  • Salicylic acid
  • Salicylic acid or derivatives
  • Hydroxybenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56. [PubMed:12852483 ]
  2. Jeske AH: COX-2 inhibitors and dental pain control. J Gt Houst Dent Soc. 1999 Nov;71(4):39-40. [PubMed:10825891 ]
  3. Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW: Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001 Oct 31;123(43):10429-35. [PubMed:11673972 ]
  4. Moore PA, Hersh EV: Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. [PubMed:11315375 ]
  5. Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53. [PubMed:8737748 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56. [PubMed:12852483 ]
  2. Chen QH, Rao PN, Knaus EE: Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem. 2005 Apr 1;13(7):2459-68. [PubMed:15755648 ]
  3. Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53. [PubMed:8737748 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Molecular Weight:
59741.035 Da
References
  1. Cheng Z, Radominska-Pandya A, Tephly TR: Studies on the substrate specificity of human intestinal UDP- lucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos. 1999 Oct;27(10):1165-70. [PubMed:10497143 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name:
TTR
Uniprot ID:
P02766
Molecular Weight:
15886.88 Da
References
  1. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW: Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem. 2004 Jan 15;47(2):355-74. [PubMed:14711308 ]
  2. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ: Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J. 2004 Jul 15;381(Pt 2):351-6. [PubMed:15080795 ]
  3. Gales L, Macedo-Ribeiro S, Arsequell G, Valencia G, Saraiva MJ, Damas AM: Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochem J. 2005 Jun 1;388(Pt 2):615-21. [PubMed:15689188 ]
  4. Miller SR, Sekijima Y, Kelly JW: Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004 May;84(5):545-52. [PubMed:14968122 ]
  5. Tojo K, Sekijima Y, Kelly JW, Ikeda S: Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006 Dec;56(4):441-9. Epub 2006 Oct 6. [PubMed:17028027 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Davilas A, Koupparis M, Macheras P, Valsami G: In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique. J Pharm Pharmacol. 2006 Nov;58(11):1467-74. [PubMed:17132209 ]
  2. Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW: Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001 Oct 31;123(43):10429-35. [PubMed:11673972 ]
  3. Rehse K, Fiedler B: [Determination of the protein binding of drugs by continuous ultrafiltration. 9. Comparison of the binding of nonsteroid antirheumatics to human serum albumin and their interaction with phenprocoumon]. Arch Pharm (Weinheim). 1989 Apr;322(4):241-3. [PubMed:2751413 ]
  4. Verbeeck RK, De Schepper PJ: Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clin Pharmacol Ther. 1980 May;27(5):628-35. [PubMed:7371361 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  2. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23